PLC Systems said that the notice of allowance signifies USPTO’s determination that the applicant is entitled to a patent under the law. The company expects the new patents to be issued later this year.

According to PLC Systems, the RenalGuard Therapy is designed to reduce the toxic effects that contrast media can have on the kidneys for patients undergoing imaging procedures. The therapy is based on the theory that creating and maintaining a high urine output allows the body to rapidly eliminate the contrast media, reducing its toxic effects.

PLC Systems expects to continue work with the USPTO as well as patent organizations in other countries to advance more patent applications concerning RenalGuard, including those covering the RenalGuard product and fluid balancing techniques and systems that remain pending.

Mark Tauscher, president and chief executive officer of PLC Systems, said: “This is a critical milestone for our company and for RenalGuard. We will to continue to build our patent position to enhance the value of our RenalGuard technology and method of CIN prevention.

“Combined with the positive results we are seeing from investigator-sponsored clinical trials of RenalGuard in Italy, this achievement provides us with heightened confidence in our future. We look forward to continuing our discussions with potential strategic and financial partners, armed with this important validation.”